Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in financing to advance its research and development. CEO Dr. John Swart announced ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

In a breakthrough that brings bioengineered organs one step closer to reality, scientists have created lab-grown liver tissue capable of forming its own blood vessels. A team from Cincinnati ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total ...

Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead ...

Myosteatosis is associated with poor outcomes in various liver diseases. However, standardized methods for assessing, defining, and diagnosing myosteatosis in the context of liver diseases remain ...